Compare Strategy Inc. (MSTR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs TG Therapeutics Inc — how do they compare? Strategy Inc. trades at $131.24 (market cap $54.24B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Strategy Inc. is far larger — about 6.4× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.
| MSTR | TGTX | |
|---|---|---|
Market Cap | $54.24B | $8.53B |
Sector | Technology | Health |
52-Week High | $359.69 | $59.06 |
52-Week Low | $82.31 | $26.94 |
Enterprise Value | $73.00B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $136.52, down 4.4% today, with a bullish technical signal from moving averages and support at $135. The company reported Q2 2026 EPS of -$24.45, missing expectations, and has a negative net income margin of -6,102.96%. Recent news highlights MSTR's partnership with Google Cloud for AI forums and a shift in capital allocation toward preferred stock buybacks instead of Bitcoin purchases.
Outlook remains speculative with high volatility; analyst consensus is bullish with a $229.64 price target, but risks include persistent earnings misses, heavy debt, and dependence on Bitcoin's performance. Institutional sentiment is mixed amid operational cash flow challenges and competitive pressures in software services.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
